Compounds which have activity at M1 receptor and their uses in medicine

US8283364B2 · kind B2 · utility

Assignee

• Glaxo Group Limited · GB

Inventors

• Brian W. Budzik · Perkiomenville, US
• David G. Cooper · Riva, US
• Ian Thomson Forbes · Harlow, GB
• Vincenzo Garzya · Harlow, GB
• Jian Jin · Suzhou, CN
• Dongchuan Shi · Collegeville, US
• Paul William Smith · Harlow, GB
• Graham Walker · Harlow, GB

Key dates

• Filing date: Sep 27, 2006
• Grant date: Oct 9, 2012
• Expiry date: Dec 16, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D235/26
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of formula (I) and salts are provided:wherein R4 is fluoro, R5 is selected from hydrogen, halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6alkoxy, and C1-6alkoxy substituted with one or more fluorine atoms; and R6 is selected from halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6alkoxy and C1-6alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C1-6alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.